Skip to main content
Shan-Wen Lui on Muck Rack

Shan-Wen Lui

As seen in: Wiley Online Library, In Vivo (IIAR)
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Shan-Wen

Contact Shan-Wen, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

Rhupus Syndrome With Multiple Drug Intolerances Managed by Reduced-dose Rituximab and Adjunctive Molecular Hydrogen Therapy: A Case Report

|
By Jeng-Wei Lu, Yi-Jung Ho, Shan-Wen Lui, Han-Luen Tsai
| In Vivo (IIAR)
Keywords: Case report Rhupus syndrome rheumatoid arthritis systemic lupus erythematosus hydrogen therapy Introduction Rhupus syndrome is an overlap condition of rheumatoid arthritis (RA) and systemic lupus erythematosus (SLE).
Open in Who Shared Issue with article?

A Case Report of Adjuvant Molecular Hydrogen Therapy in Refractory Rheumatoid Arthritis With Atlantoaxial Subluxation

|
By Jeng-Wei Lu, Yi-Jung Ho, Shan-Wen Lui, You-Chi Ren
| In Vivo (IIAR)
Keywords: Case report rheumatoid arthritis hydrogen therapy Treg cell Breg cell atlantoaxial subluxation Introduction Rheumatoid arthritis (RA) is a common chronic inflammatory disease that primarily affects the joints but also presents with extra-articular manifestations, which affect multiple organ systems and contribute to comorbidities such as cardiovascular, pulmonary, gastrointestinal, and neurological diseases (1, 2).
Open in Who Shared Issue with article?

Predicting Therapeutic Response to Molecular Hydrogen in Autoimmune Diseases via Immunophenotyping

|
By Shan-Wen Lui, Ting-Yu Hsieh, Jeng-Wei Lu, Biotech Research
| Wiley Online Library Verified
Conflicts of Interest The authors declare no conflicts of interest. Supporting Information Filename Description apm70040-sup-0001-AppendixS1.docxWord 2007 document , 17.7 MB Supporting Information S1. Medication usage of the participants in the study. Supporting Information S2. Baseline characteristics and 3-Month changes in clinical parameters between MHAT-treated and non-treated RA patients. Supporting Information S3. The fluorescent corresponding antibodies. Supporting Information S4.
Open in Who Shared Issue with article?
See all 10 articles